文献速递脑血管病

重新思考时效性卒中试验的知情同意:COVID-19 大流行的启示

Rethinking Consent for Stroke Trials in Time-Sensitive Situations: Insights From the COVID-19 Pandemic.
PubMed 文献 · Stroke · 2021-02-16

本文为观点文章,讨论 COVID-19 大流行期间临床研究知情同意面临的挑战,探讨在特殊情况下调整现有同意流程是否可接受,并提出一个含预设标准和制衡机制的框架,以在特殊情况下最大化患者获益而不损害患者自主权。

要点

  • 大流行导致物理隔离和医生工作负荷增加,使及时获得知情同意成为临床试验瓶颈。
  • 文章探讨在特殊情况下调整知情同意流程的可接受性。
  • 提出含预设标准和制衡机制的框架,以在特殊情况下调整同意流程。

核心结论

  • 在 COVID-19 大流行等特殊情况下,可考虑通过含预设标准和制衡机制的框架调整知情同意流程,以最大化患者获益而不损害患者自主权。

研究设计与样本

  • 本文为观点文章,讨论 COVID-19 大流行期间知情同意面临的挑战及可能的调整框架。

主要发现

  • 物理隔离措施和医生工作负荷增加使知情同意流程复杂化。
  • 及时且充分的患者同意已成为许多临床试验的瓶颈。

关键数值与推荐

  • 文章提出一个含预设标准和制衡机制的框架,允许在特殊情况下调整现有同意流程。

临床怎么用

  • 在特殊情况下可参考该框架评估是否调整知情同意流程,以平衡患者获益与自主权。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Informed consent is a key concept to ensure patient autonomy in clinical trials and routine care. The coronavirus disease 2019 (COVID-19) pandemic has complicated informed consent processes, due to physical distancing precautions and increased physician workload. As such, obtaining timely and adequate patient consent has become a bottleneck for many clinical trials. However, this challenging situation might also present an opportunity to rethink and reappraise our approach to consent in clinical trials. This viewpoint discusses the challenges related to informed consent during the COVID-19 pandemic, whether it could be acceptable to alter current consent processes under these circumstances, and outlines a possible framework with predefined criteria and a system of checks and balances that could allow for alterations of existing consent processes to maximize patient benefit under exceptional circumstances such as the COVID-19 pandemic without undermining patient autonomy.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Goyal M, Ospel JM, Ganesh A, et al. Rethinking Consent for Stroke Trials in Time-Sensitive Situations: Insights From the COVID-19 Pandemic. Stroke. 2021. PMID: 33588599. doi:10.1161/STROKEAHA.120.031976

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。